The Invention Return on NIH Investments

Around 8 percent of grants funded by the National Institutes of Health resulted in patents.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NATIONAL EYE INSTITUTEFrom 1980 to 2007, a little more than 8 percent of the grants given out by the National Institutes of Health (NIH) led to patents, according to an analysis published in Science Thursday (March 30). Roughly 30 percent of grants over that time period were cited by patents, indicating indirect contributions to inventions as well.

“Their findings here demonstrate that there is commercial value to funding basic science,” Ross DeVol, chief research officer at the Milken Institute, told Nature News. “That may be the most important piece of this, to be quite frank.”

The authors of the study looked at more than 365,000 grants awarded during the time period, of which nearly 31,000 were directly linked to patented inventions.

They also found that basic research was nearly as likely to contribute to a patent as applied projects. The authors separated grants awarded through a request for applications (RFA)—indicating a focus on addressing a particular disease—from those that were unsolicited—likely representing more basic science—and discovered a similar citation rate in associated patents.

“One interpretation of this is that ‘basic’ research is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies